ClinicalTrials.gg

Program

epcoritamab

Also written as “Epcoritamab”, “Epcoritamab (monotherapy)” and “Epcoritamab (maintenance)”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Lymphoma, B-Cell · Lymphoma, Non-Hodgkin, led by Genmab.

Furthest: phase 3, since Nov 9, 202013 company-led studies, 12 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genmab1312 open or runningphase 3since Nov 9, 2020Jun 7, 2018Mar 2027phase 2 · NCT05451810

Also a collaborator on its studies: AbbVie and Eli Lilly.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 7, 2018First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT03625037 · 666 enrolled · United States, Australia, Canada and more
  2. Aug 25, 2020Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04542824 · 78 enrolled · Japan
  3. Oct 27, 20202 phase 2 studiesNCT04663347, NCT04623541
  4. Nov 9, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04628494 · 483 enrolled · United States, Australia, Austria and more
  5. Jan 18, 2022Phase 2 study in Lymphoma, B-CellNCT05201248 · 49 enrolled · China
  6. Jan 21, 2022Phase 1 study in Lymphoma, Non-HodgkinNCT05206357 · 17 enrolled · United States, Australia, Belgium and more
  7. Jun 3, 2022Phase 3 study in Lymphoma, FollicularNCT05409066 · 549 enrolled · United States, Argentina, Australia and more
  8. Jul 6, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05451810 · 184 enrolled · United States, Puerto Rico
  9. Nov 29, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05660967 · 111 enrolled · United States, Austria, Belgium and more
  10. Dec 20, 2023Phase 3 study in Lymphoma, FollicularNCT06191744 · 1,095 enrolled · United States, Australia, Belgium and more
  11. Jul 11, 2024Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06508658 · 379 enrolled · United States, Argentina, Australia and more
  12. Nov 6, 2025Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07226752 · 72 enrolled · China
  13. Nov 4, 2026Primary completion moved from 2026-09 to 2027-10Date moved laterphase 2 · +13 months · NCT05201248

Ahead

  1. Mar 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05451810
  2. Sep 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04542824
  3. Sep 30, 2027Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04663347
  4. Oct 2027Primary completion: phase 2 study in Lymphoma, B-CellNCT05201248

TargetBeta

CD3E →MS4A1 →read by rule
“B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07226752Lymphoma, Large B-Cell, Diffuse · China3Active, not recruitingOct 13, 202572
NCT06508658Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more3Active, not recruitingMar 2028379
NCT06191744Lymphoma, Follicular · United States, Australia, Belgium and more3Active, not recruitingNov 20371,095
NCT05660967Lymphoma, Large B-Cell, Diffuse · United States, Austria, Belgium and more2TerminatedJun 10, 2026111
NCT05451810Lymphoma, Large B-Cell, Diffuse · United States, Puerto Rico2Active, not recruitingMar 2027184
NCT05409066Lymphoma, Follicular · United States, Argentina, Australia and more3Active, not recruitingDec 2029549
NCT05206357Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more1Active, not recruitingNov 202817
NCT05201248Lymphoma, B-Cell · China2Active, not recruitingOct 202749
NCT04628494Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more3Active, not recruitingOct 13, 2025483
NCT04663347Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more2Active, not recruitingSep 30, 2027543
NCT04623541Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more2Active, not recruitingDec 2027194
NCT04542824Lymphoma, Large B-Cell, Diffuse · Japan2Active, not recruitingSep 202778
NCT03625037Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more2Active, not recruitingJan 2029666

How it is read

Names in the registry

  • “Epcoritamab”, 25 entries
  • “Epcoritamab (monotherapy)”, 1 entry
  • “Epcoritamab (maintenance)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.